<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03411200</url>
  </required_header>
  <id_info>
    <org_study_id>PACE-Mobil-PBL</org_study_id>
    <nct_id>NCT03411200</nct_id>
  </id_info>
  <brief_title>Patient Activation Through Counseling, Exercise and Mobilization</brief_title>
  <acronym>PACE-Mobil</acronym>
  <official_title>Engaging the Older Cancer Patient; Patient Activation Through Counseling, Exercise and Mobilization - Pancreatic, Biliary Tract, and Lung Cancer (PACE-Mobil-PBL) - a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Herlev and Gentofte Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Herlev and Gentofte Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PACE-Mobil-PBL is a prospective randomized controlled trial. The aim is to investigate the
      effect of a multimodal and exercise-based intervention among older patients with advanced
      pancreatic cancer, biliary tract cancer, or lung cancer during treatment with first-line
      palliative chemotherapy, immunotherapy or targeted therapy.

      The hypotheses: That the multimodal intervention will increase or maintain physical function
      levels and strength, reduce symptoms and side-effects, improve quality of life, reduce
      treatment-related complications and hospital admissions, and reduce risk of cancer cachexia
      and sarcopenia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 4, 2018</start_date>
  <completion_date type="Anticipated">May 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be randomized 1:1 to the intervention group and control group.</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>All physical tests will be conducted by masked health care professionals.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Lower body strength measured with the 30-second chair stand test</measure>
    <time_frame>Change measures (baseline, 6 weeks, 12 weeks, and 16 weeks)</time_frame>
    <description>Number of stands a participant can complete in 30-seconds from a seated position with their arms crossed over the chest. The assessments will be conducted by a blinded physiotherapist</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recruitment rate</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Number of participants included from eligible patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to exercise sessions</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Number of exercise sessions attended out of planned sessions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to counseling sessions</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Number of counseling sessions attended out of planned sessions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Cases of exercise-related injuries or events, including, but not restricted to musculoskeletal-related events, falls, fall-related injuries, bleedings, or cardiovascular events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical performance measured with the 6-minute-walk-test</measure>
    <time_frame>Change measures (baseline, 6 weeks, 12 weeks, and 16 weeks)</time_frame>
    <description>The distance (measured in meters) a participant is able to walk over a total of six minutes on a hard flat surface. The assessments will be conducted by a blinded physiotherapist</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical performance measured with the 6-meter Gait Speed Test</measure>
    <time_frame>Change measures (baseline, 6 weeks, 12 weeks, and 16 weeks)</time_frame>
    <description>The assessments will be conducted by a blinded physiotherapist</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Upper-body strength measured with the Handgrip Strength Test</measure>
    <time_frame>Change measures (baseline, 6 weeks, 12 weeks, and 16 weeks)</time_frame>
    <description>Handgrip strength will be measured using a hand-held Jamar dynamometer. The assessments will be conducted by a blinded physiotherapist</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical activity level</measure>
    <time_frame>Change measures (baseline, and 12 weeks).</time_frame>
    <description>Step Counts (measured with Garmin Vivofit 3 activity tracker).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Qualitative assessment of participants' experiences</measure>
    <time_frame>After 12 weeks</time_frame>
    <description>Qualitative individual semi-structured interviews with participants from the intervention group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Change measures (baseline, 6 weeks, 12 weeks, and 16 weeks)</time_frame>
    <description>Measured with the EORTC Quality of Life questionnaire (EORTC QLQ-C30)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms of depression</measure>
    <time_frame>Change measures (baseline, 6 weeks, 12 weeks, and 16 weeks)</time_frame>
    <description>Measured with the patient questionnaire 'Hospital Anxiety and Depression Scale' (HADS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms of anxiety</measure>
    <time_frame>Change measures (baseline, 6 weeks, 12 weeks, and 16 weeks)</time_frame>
    <description>Measured with the 'Hospital Anxiety and Depression Scale' (HADS) patient questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom burden</measure>
    <time_frame>Change measures (baseline, 6 weeks, 12 weeks, and 16 weeks)</time_frame>
    <description>Measured with the 'M.D. Anderson Symptom Inventory' patient questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with side-effects to oncological treatment assessed with the Common Toxicity Criteria for Adverse Events version 4</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Data will be collected from medical charts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight</measure>
    <time_frame>Change measures (baseline, 6 weeks, 12 weeks, and 16 weeks)</time_frame>
    <description>Weight will be measured using standard procedures (no shoes, light clothing) and will be reported in kilograms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body mass index</measure>
    <time_frame>Change measures (baseline, 6 weeks, 12 weeks, and 16 weeks)</time_frame>
    <description>Reported in kg/m^2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whole-body Lean body mass (LBM)</measure>
    <time_frame>Change measures (baseline, and 12 weeks)</time_frame>
    <description>Measured with Bioimpedance and DXA scans</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whole-body fat mass</measure>
    <time_frame>Change measures (baseline, and 12 weeks)</time_frame>
    <description>Measured with Bioimpedance and DXA scans</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whole-body bone mineral density</measure>
    <time_frame>Change measures (baseline, and 12 weeks)</time_frame>
    <description>Measured with DXA scans</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation (inflammatory biomarkers: C-reactive protein, Interleukin 6, YKL-40)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Data will be collected from medical charts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hospital admissions</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Data will be collected from medical charts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Causes of hospitalizations</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Data will be collected from medical charts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospitalizations (days)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Data will be collected from medical charts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Data will be collected from medical charts</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Pancreas Cancer</condition>
  <condition>Biliary Tract Cancer</condition>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>Advanced Cancer</condition>
  <arm_group>
    <arm_group_label>Intervention group (n=50)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in the intervention group will receive usual care and the multimodal and exercise-based intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group (n=50)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants in the control group will receive usual care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Multimodal and exercise-based intervention</intervention_name>
    <description>The multimodal and exercise-based intervention is comprised of:
Supervised and group-based exercise two times a week (60 minutes per session). The program consists of warm-up, exercises for balance and flexibility, progressive resistance training, and stretching and relaxation.
Individualized activity program based on step counts (with activity tracker). Based on each participant's starting point, preferences and motivation, an individualized program will be composed. Evaluation and goal-setting will be conducted once weekly.
Nurse-led supportive and motivational counseling; each participant will be invited to two sessions of counseling (in week 1 + 6). Each session will be based on a holistic assessment of each participant's life situation. Advice and counseling will be provided based on identified problems and needs.
A nutritional supplement (protein bar or drink) will be served to participants immediately after the supervised exercise session.</description>
    <arm_group_label>Intervention group (n=50)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria, participants must:

          -  Be diagnosed with locally advanced or metastatic pancreatic cancer, OR locally
             advanced or metastatic biliary tract cancer, OR locally advanced or metastatic
             non-small cell lung cancer within 12 weeks.

          -  Have unresectable cancer.

          -  Be treated with first-line palliative chemotherapy, immunotherapy or targeted therapy
             at the Department of Oncology, Herlev and Gentofte Hospital.

          -  Have an Eastern Cooperative Oncology Group (ECOG) performance status â‰¤2.

          -  Have the ability to speak and read Danish, and to provide a signed informed consent
             form.

        Exclusion Criteria, patients with:

          -  Small-cell lung cancer.

          -  Any physical condition that hinder the execution of physical exercise training.

          -  Documented and uncontrolled brain metastases that hinder participation in an
             exercise-based trial, based on the referring oncologist's assessment.

          -  Dementia, psychotic disorders, or other cognitive diseases or conditions that hinder
             participation in a clinical exercise-based trial.

          -  Unstable medical disease or history of serious or concurrent illness; any Medical
             condition that might be aggravated by exercise training or that cannot be controlled,
             including, but not restricted to congestive heart failure (NYHA class II-IV), unstable
             angina pectoris, implantable cardioverter defibrillator, or myocardial infarction
             within 6 months, based on the referring oncologist's assessment.

        In patients with bone metastases:

        - A bone metastatic burden or location that poses a risk of injury in the performance of
        exercise training, as assessed by the referring oncologist.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marta Kramer Mikkelsen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marta Kramer Mikkelsen, MHSc</last_name>
    <phone>0045 38689579</phone>
    <email>marta.kramer.mikkelsen.02@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dorte Nielsen, Prof., DMSc</last_name>
    <email>Dorte.Nielsen.01@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Herlev and Gentofte Hospital, Department of Oncology</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta Kramer Mikkelsen, MHSc</last_name>
      <phone>+45 38689579</phone>
      <email>marta.kramer.mikkelsen.02@regionh.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2018</study_first_submitted>
  <study_first_submitted_qc>January 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 26, 2018</study_first_posted>
  <last_update_submitted>April 4, 2018</last_update_submitted>
  <last_update_submitted_qc>April 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Marta Kramer Mikkelsen</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Older</keyword>
  <keyword>Advanced Cancer</keyword>
  <keyword>Exercise</keyword>
  <keyword>Resistance training</keyword>
  <keyword>Counseling</keyword>
  <keyword>Mobilization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Biliary Tract Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

